0001493152-23-036351.txt : 20231005 0001493152-23-036351.hdr.sgml : 20231005 20231005160537 ACCESSION NUMBER: 0001493152-23-036351 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230929 ITEM INFORMATION: Changes in Registrant's Certifying Accountant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231005 DATE AS OF CHANGE: 20231005 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oncocyte Corp CENTRAL INDEX KEY: 0001642380 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 271041563 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37648 FILM NUMBER: 231311374 BUSINESS ADDRESS: STREET 1: 15 CUSHING CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-409-7600 MAIL ADDRESS: STREET 1: 15 CUSHING CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: OncoCyte Corp DATE OF NAME CHANGE: 20200213 FORMER COMPANY: FORMER CONFORMED NAME: Oncocyte Corp DATE OF NAME CHANGE: 20200205 FORMER COMPANY: FORMER CONFORMED NAME: OncoCyte Corp DATE OF NAME CHANGE: 20150513 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): September 29, 2023

Oncocyte Corporation

(Exact name of registrant as specified in its charter)

California	1-37648	27-1041563
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

15 Cushing

Irvine, California 92618

(Address of principal executive offices)

(949) 409-7600

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, no par value		OCX		The Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 4.01. Changes in Registrant’s Certifying Accountant.

The Audit Committee of the Board of Directors (the “Audit Committee”) of Oncocyte Corporation (the “Company”), as a matter of good governance, invited several registered public accounting firms to participate in an evaluation process to consider a potential audit firm rotation.

As a result of this process, the Audit Committee approved the engagement of Marcum LLP (“Marcum”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, subject to Marcum’s completion of their client acceptance procedures. The Company has dismissed WithumSmith+Brown, PC (“Withum”) as independent registered public accounting firm of the Company on September 29, 2023. The Company expects to receive a fully executed engagement letter from Marcum on or about October 9, 2023.

Withum’s report on the Company’s consolidated financial statements as of and for the fiscal years ended December 31, 2021 and December 31, 2022, did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.

During the fiscal years ended December 31, 2021 and December 31, 2022, and the subsequent interim period through June 30, 2023, there were (i) no “disagreements” as that term is defined in Item 304(a)(1)(iv) of Regulation S-K, between the Company and Withum on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Withum, would have caused Withum to make reference to the subject matter of the disagreement in their reports on the financial statements for such years, and (ii) no “reportable events” as that term is defined in Item 304(a)(1)(v) of Regulation S-K, except for the material weaknesses related to the failure to design and maintain effective controls to address the initial application of complex accounting standards and accounting treatment of non-routine, unusual or complex events and transactions, which material weakness was remediated prior to June 30, 2023, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023.

The Company provided Withum with a copy of the disclosures it is making in this Current Report on Form 8-K. The Company requested that Withum furnish a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the statements made herein. A copy of Withum’s letter dated October 5, 2023 is attached as Exhibit 16.1 hereto.

During the fiscal years ended December 31, 2021 and December 31, 2022, and the subsequent interim period through June 30, 2023, neither the Company nor anyone acting on its behalf has consulted with Marcum with respect to (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that Marcum concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue, or (ii) any matter that was either the subject of a “disagreement” or “reportable event” as those terms are defined in Item 304(a)(1) of Regulation S-K.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this Current Report may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact contained in this Current Report. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
16.1		Letter of WithumSmith+Brown, PC, dated October 5, 2023
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ONCOCYTE CORPORATION

Date: October 5, 2023	By:	/s/ Joshua Riggs
		Joshua Riggs
		President and Chief Executive Officer

EX-16.1 2 ex16-1.htm

Exhibit 16.1

October 5, 2023

Office of the Chief Accountant

Securities and Exchange Commission

100 F Street, NE

Washington, D.C. 20549

Ladies and Gentlemen:

We have read Oncocyte Corporation statements included under Item 4.01 of its Form 8-K dated October 5, 2023. We agree with the statements made in paragraphs one through four discussing Oncocyte Corporation’s relationship with WithumSmith+Brown, PC. We are not in a position to agree or disagree with other statements contained therein including the remediation of the material weakness related to the failure to design and maintain effective controls to address the initial application of complex accounting standards and accounting treatment of non-routine, unusual or complex events and transactions.

Very truly yours,

/s/ WithumSmith+Brown, PC

East Brunswick, New Jersey

EX-101.SCH 3 ocx-20230929.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ocx-20230929_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ocx-20230929_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Sep. 29, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Sep. 29, 2023
Entity File Number	1-37648
Entity Registrant Name	Oncocyte Corporation
Entity Central Index Key	0001642380
Entity Tax Identification Number	27-1041563
Entity Incorporation, State or Country Code	CA
Entity Address, Address Line One	15 Cushing
Entity Address, City or Town	Irvine
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92618
City Area Code	(949)
Local Phone Number	409-7600
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, no par value
Trading Symbol	OCX
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001642380 2023-09-29 2023-09-29 iso4217:USD shares iso4217:USD shares 0001642380 false 8-K 2023-09-29 Oncocyte Corporation CA 1-37648 27-1041563 15 Cushing Irvine CA 92618 (949) 409-7600 Common Stock, no par value OCX NASDAQ false false false false false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / " 3\0 M !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " "R@$57)!Z;HJT #X 0 M&@ @ &?$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0 M2P$"% ,4 " "R@$5799!YDAD! #/ P $P @ &$$@ I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #.$P ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://oncocyte.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ocx-20230929.xsd ocx-20230929_lab.xml ocx-20230929_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "OCX", "nsuri": "http://oncocyte.com/20230929", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "ocx-20230929.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ocx-20230929_lab.xml" ] }, "presentationLink": { "local": [ "ocx-20230929_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://oncocyte.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-09-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001493152-23-036351-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-036351-xbrl.zip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